Indications
Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms.
Composition
- Active substance
- reteplase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rapilysin
- Active substance
- reteplase
- ATC code
- B01AD07
- Therapeutic area
- Myocardial Infarction
- Marketing authorisation holder
- Actavis Group PTC ehf
- Status
- Withdrawn